Kala Pharmaceuticals has won FDA approval for a drug developed to treat pain and inflammation following eye surgery.
While the approval is new, the drug, loteprednol etabonate (Inveltys), is not. Kala’s drug is a new formulation of a Bausch Health (NYSE: BHC) topical steroid that is approved to treat pain and inflammation after eye surgeries. Both are eye drops. The difference is the version from Waltham, MA-based Kala uses nanoparticle technology intended to more efficiently deliver the therapeutic through the barriers of mucous in the eyes.
Compared to Baush’s drug, Kala says its product offers better efficacy and safety, and… Read more »
UNDERWRITERS AND PARTNERS